FDA clears Carl Zeiss' OCT (Optical Coherence Tomographer) screener for retinal diseases:
This article was originally published in Clinica
Executive Summary
Carl Zeiss Ophthalmic Systems has received US FDA clearance to market its Optical Coherence Tomographer (OCT) model 3000 for screening for retinal diseases. The device provides real-time cross-sectional images of retinal tissue that have axial resolution of ten microns or less. It enables physicians to avoid invasive procedures and see below the surface of the retina, allowing them to directly measure internal retinal structures that can help in the diagnosis of diseases, such as glaucoma. A typical examination using the device takes less than 10 minutes, says the Dublin, California firm.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.